Skip to Content

Ubrogepant Approval Status

FDA Approved: No (Pending Approval)
Generic name: ubrogepant
Company: Allergan plc
Treatment for: Migraine

Ubrogepant is a potent, orally-administered CGRP receptor antagonist in development for the acute treatment of migraine.

Development Status and FDA Approval Process for ubrogepant

DateArticle
Mar 11, 2019Allergan Announces FDA Acceptance of New Drug Application for Ubrogepant for the Acute Treatment of Migraine
Apr 27, 2018Allergan Announces Second Positive Phase 3 Clinical Trial for Ubrogepant -- an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine
Feb  6, 2018Allergan Announces Positive Top Line Phase 3 Results for Ubrogepant - an Oral CGRP Receptor Antagonist for the Acute Treatment of Migraine

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Hide